RxDoctor Payments DataLook up a doctor →

Charles Athill, MD

Clinical Cardiac Electrophysiology · San Diego, CANPI 1174504252

Payments from drug & device makers

$1,174,507in general payments, 2019–2025

Across 934 payments — averaging $1257.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$515K
  • Biosense Webster, Inc.$309K
  • Boston Scientific$140K
  • Medical Device Business Services, Inc.$130K
  • Abbott$45K
  • Johnson & Johnson$17K
  • plus $19K from 36 others

What the payments were for

  • Consulting fees$112,45057%
  • Speaking & faculty fees$43,40022%
  • Travel & lodging$17,9899%
  • Food & beverage$21,83811%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,174,507 in reported general payments places this provider in the 95th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California

Medicare billing

Part B allowed, 2024
$435,932
Medicare patients
937
Services billed
4,367

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban181$222,976
XareltoRivaroxaban114$160,376
MultaqDronedarone Hcl32$50,351
EntrestoSacubitril/Valsartan13$20,940
JardianceEmpagliflozin14$12,935
Dofetilide55$8,638
Flecainide Acetate82$4,369
Metoprolol Succinate158$2,890
SotalolSotalol Hcl55$1,614
Ezetimibe20$1,032
Valsartan13$765
Rosuvastatin Calcium39$646
Amiodarone Hcl57$621
Nifedipine ErNifedipine25$464
Metoprolol Tartrate79$452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$90$222,976181 claims
Johnson & JohnsonXarelto$16,922$160,376114 claims
Sanofi-aventis U.S. LLCMultaq$12$50,35132 claims
NovartisEntresto$302$20,94013 claims
Boehringer IngelheimJardiance$78$12,93514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in San Diego

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →